Race Oncology signs distribution deal with BL&H Korea

Australian-listed pharmaceutical company Race Oncology has signed an exclusive licence agreement with BL&H Korea for the sale of Bisantrene, an agent for the treatment of acute myelogenous leukaemia, under a named patient program (NPP).

The NPP mechanism in South Korea allows for pre-approval access and sales of medicines in response to requests by physicians on behalf of specific, or “named”, patients.

“We are very excited to bring Bisantrene to the South Korean market. Bisantrene represents a unique commercial opportunity for our company because of its clinical benefits for AML patients,” said DC Roh, president, BL&H.

Race Oncology’s CEO Peter Molloy said the deal signals the commercial potential for Bisantrene NPP partnerships in Asia and anticipated NPP launches in Europe commencing later this year.